GT Biopharma wins FDA clearance for GTB-5550 multiple myeloma trial
AI Summary- GT Biopharma received FDA IND clearance to study GTB-5550 in multiple myeloma.
- $11 million in cash as of September 15 is expected to fund operations into Q3 2027.
- The solid-tumor GTB-5550 basket trial continues enrollment, with an update expected in Q4 2026.